Translating Research into Clinical Scale Manufacturing of Mesenchymal Stromal Cells by Karen Bieback, Sven Kinzebach, Marianna Karagianni

“…The challenge relates to managing the expected therapeutic benefits with the potential risks and to balance the fast move to clinical trials with time-consuming cautious risk assessment. …”
Get full text

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment by Ze-Tao Zhan, Lu Liu, Ming-Zhen Cheng, Yi Gao, Wei-Jie Zhou

“…Based on this study, further clinical trials are expected.…”
Get full text

The Relationship Between the Modulation of Intestinal Microbiota and the Response to Immunotherapy in Patients with Cancer by Laura Radoš, Marin Golčić, Ivana Mikolašević

“…Fecal transplantation is a safe and realistic adjuvant option for the treatment of cancer patients with immunotherapy, but more clinical trials are necessary. Modulating the microbiota composition indeed changes the effectiveness of immunotherapy, but in the future, more human studies should be organized to precisely determine the types and procedures of microbiota modulation.…”
Get full text

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy by Zunaira Qureshi, Murtaza Najabat Ali, Minahil Khalid

“…Treating painful symptoms in diabetic patient can be frustrating not only for the patients but also for health care workers, so additional clinical trials for novel and conventional treatments are required to devise more effective treatment for PDN with minimal side effects. …”
Get full text

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes by María Isabel del Olmo-Garcia, Juan Francisco Merino-Torres

“…On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been conducted with GLP-1 RAs. …”
Get full text

Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis by Pascal Lapierre, Alain Lamarre

“…With the recent advent of monoclonal antibodies able to target regulatory T cells (daclizumab) and improve immune responses and several ongoing clinical trials analysing the impact of regulatory T cell infusion on autoimmune liver disease or liver transplant tolerance, modulation of immunological tolerance through CD4+ regulatory T cells could be a key element of future immunotherapies for several liver diseases allowing restoring the balance between proper immune responses and tolerance.…”
Get full text

The Microbiome-Gut-Brain Axis, Nutrition and Parkinson’s Disease by Jevgenija Guk, Rūta Kaladytė Lokominienė, Dalius Jatužis

“…Although epidemiological and experimental studies in animal models have shown their neuroprotective properties, their effectiveness was not confirmed in clinical trials. However, daily food intake comprises many nutrients that can interact and produce either a synergistic or antagonistic effect on the human body. …”
Get full text

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature by Ioanna Tsiouprou, Athanasios Zaharias, Dionisios Spyratos

“…During the past few years, several clinical trials have evaluated the effect of addition of immunotherapy to conventional chemotherapy in patients with extensive SCLC. …”
Get full text

Targeting Apoptosis Pathways in Cancer with Alantolactone and Isoalantolactone by Azhar Rasul, Muhammad Khan, Muhammad Ali, Jiang Li, Xiaomeng Li

“…This review suggests that alantolactone and isoalantolactone are potential promising anticancer candidates, but additional studies and clinical trials are required to determine their specific intracellular sites of actions and derivative targets in order to fully understand the mechanisms of therapeutic effects to further validate in cancer chemotherapy.…”
Get full text

Case report: Exploring efficacy of tofacitinib in modulating interferon response in five case of anti-MDA5+ dermatomyositis with interstitial lung disease by Jie Zhao, Yan Bao, Ying Gao, Keliang Xie

“…Urgent and well-designed clinical trials are imperative to unravel the intricate interplay between RP-ILD and the IFN signature in MDA5-DM, and to evaluate novel therapeutic targets that promise long-term efficacy and safety.…”
Get full text

A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines by Jose Miguel Rubio-Perez, Juana Maria Morillas-Ruiz

“…It has been observed in epidemiological studies that treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the risk for developing AD. Unfortunately, clinical trials of NSAIDs in AD patients have not been very fruitful. …”
Get full text

Combined Effect of Lentinan and Cisplatin on Cytokines IL-6, TNF-α, and TGF-β in Tumor Therapy by Xu-dong Liu, Min Li, Wan-xiang Li, Qing-yu Wang, Hong-xia Zhang

“…Many cytokines have shown positive effect on different malignancies in clinical trials. Studies have shown that such cytokines as IL6, TNF-α, and TGF-β play a quite important role in the formation of tumor microenvironment. …”
Get full text

Functional Multipotency of Stem Cells: What Do We Need from Them in the Heart? by Pablo Díez Villanueva, Ricardo Sanz-Ruiz, Alberto Núñez García, María Eugenia Fernández Santos, Pedro L. Sánchez, Francisco Fernández-Avilés

“…After more than ten years of human research in the field of cardiac regenerative medicine, application of stem cells in different phases of ischemic heart disease has come to age. Randomized clinical trials have demonstrated that stem cell therapy can improve cardiac recovery after the acute phase of myocardial ischemia and in patients with chronic ischemic heart disease, and several efficacy phase III trials with clinical endpoints are on their way. …”
Get full text

Prediction of hemolytic peptides and their hemolytic concentration by Anand Singh Rathore, Nishant Kumar, Shubham Choudhury, Naman Kumar Mehta, Gajendra P. S. Raghava

“…Abstract Peptide-based drugs often fail in clinical trials due to their toxicity or hemolytic activity against red blood cells (RBCs). …”
Get full text

PPAR Agonists and Cardiovascular Disease in Diabetes by Anna C. Calkin, Merlin C. Thomas

“…Many of these potentially anti-atherosclerotic effects are thought to be mediated by transrepression of nuclear factor-kB, STAT, and activator protein-1 dependent pathways. In recent clinical trials, PPAR𝛼 agonists have been shown to be effective in the primary prevention of cardiovascular events, while their cardiovascular benefit in patients with established cardiovascular disease remains equivocal. …”
Get full text

A SYSTEMATIC REVIEW OF THE USE OF TULATHROMYCIN IN VETERINARY MEDICINE by Carmen (Pop) Moldovan, Alexandra Dreancă, Oana Rotar, Mihai Madru, Ioan Marcus

“…Additionally, the review examines the dosage regimens, administration routes, and potential side effects reported in clinical trials. Data regarding antimicrobial resistance to tulathromycin is discrepant due to several sources that display negative results regarding the sole use of this macrolide and its off-label use. …”
Get full text

Update of Immunomodulatory Therapy for Inflammatory Bowel Disease by Charles N Bernstein

“…Newer immunomodulatory agents have been designed for specific targets. and in particular monoclonal antibodies that block the effects of interleukin-1, tumour necrosis factor-alpha and the T cell receptor are available for clinical trials. We are in an era of expanding therapeutic approaches to these diseases, including the refined use of readily available agent, the development of newer, more targeted agents and a broader understanding of how agents may be effectively used simultaneously or sequentially.…”
Get full text

Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments by Michael P. Kahle, Gregory J. Bix

“…It is important for preclinical stroke researchers to frequently consider and revisit these concepts, especially since promising experimental stroke treatments continue to fail in human clinical trials. Therefore, this paper will focus on considerations for several key aspects of preclinical stroke studies including the selection and execution of the animal stroke model, drug/experimental treatment administration, and outcome measures to improve experimental validity and translation potential. …”
Get full text

Stem Cells for Cardiac Repair: Status, Mechanisms, and New Strategies by Ren Mingliang, Zhang Bo, Wang Zhengguo

“…It is expected to replace and repair damaged myocardium. But many clinical trials have shown that the stem cell therapy of heart failure is modest or not effective. …”
Get full text

Intravenous γ Globulin for Intractable Abdominal Pain due to IgA Vasculitis by George Naifa, George Totikidis, Sonia Alexiadou, Christina Kolona, Elpis Mantadakis

“…Given the toxicity and/or need for long-term administration of other second-line immunosuppressive therapies in corticosteroid-resistant IgA vasculitis, such as rituximab, cyclosporine, cyclophosphamide, azathioprine, or colchicine, we propose that IVIg may be a useful and safe treatment option, although randomized controlled clinical trials are needed in order to clarify its role in the treatment of abdominal pain in IgA vasculitis.…”
Get full text